Keyword: Flagship Pioneering
Kintai Therapeutics' anti-obesity candidate KTX-0200 showed sustained weight loss and improved glucose control and liver health in rodents.
Welcome to our pre-Christmas news of note, as we gather up bite-size news from around biotech.
Days after leaving Bristol-Myers Squibb (and amid its big merger deal with Celgene), former dealmaker Paul Biondi has landed at a major biotech VC.
Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.
As Flagship officially launches Cygnal, the startup is filling in some details, including how its tech works and where it wants to go beyond cancer
Omega Therapeutics is working on treatments that adjust gene expression up or down without making permanent changes to the genome.
Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”
Paul-Peter Tak joins Kintai Therapeutics as it steers its “precision enteric medicines” toward the clinic, with the first trials slated to start in 2020.
The goal is to genetically modify and differentiate stem cells to create cell therapies that are cloaked from the immune system.
Flagship Pioneering has raised $824 million for a fund to support biotech and health companies that have come up through its Flagship Labs foundry.